Glaucoma and Dry Eye

Glaucoma and dry eye frequently coexist, and the relationship deserves attention because treating one can affect the other. Glaucoma is a disease of the optic nerve, usually managed by lowering intraocular pressure, most often with long-term daily eye drops. Those drops, and the disease's typical age group, make ocular surface disease especially common in glaucoma patients.

Why surface disease is so common in glaucoma

Many glaucoma medications are used chronically and, particularly when they contain preservatives, can irritate and inflame the ocular surface over years of use. The result is a high rate of coexisting dry eye disease and meibomian gland dysfunction in this population. This matters for comfort, for adherence to the very drops that protect the optic nerve, and for the reliability of measurements taken from a compromised surface.

Why it is easy to overlook

When the priority is protecting vision by controlling pressure, the ocular surface can be neglected, yet burning, grittiness and irritation are common and undertreated in glaucoma patients. Recognising and managing the surface disease improves quality of life and can support better adherence to glaucoma therapy.

How surface care fits

Caring for the ocular surface alongside glaucoma treatment is the goal. Light-based therapy that addresses inflammation and gland dysfunction, such as LM™ LLLT photobiomodulation, offers a route to treat the surface disease without adding to the patient's drop burden, complementing rather than replacing glaucoma management. Any plan is coordinated with the clinician managing the glaucoma, and treatments are used within their cleared indications.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.